WebMar 30, 2023 · The dividend of 5 million shares of MiNK common stock will be made to all Agenus shareholders of record as of April 17, 2023, on a pro rata basis. The Dividend …
- People also ask
Agenus cell therapy spinoff MiNK inks mark on Wall Street with …
WebOct 15, 2021 · biotech IPO Cell & Gene Therapy COVID-19 graft-versus-host disease. MiNK Therapeutics inked its spot on the Nasdaq with a $40 million initial public offering Friday …
WebFeb 14, 2024 · First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and …
Agenus Inc. (AGEN) Stock Price, News, Quote & History - Yahoo …
WebThe company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta …
WebAgenus subsidiary MiNK Therapeutics announces IPO and becomes publicly traded on Nasdaq under the symbol INKT. Agenus subsidiary SaponiQx launches to drive …
WebAgenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of …
WebOn May 1 st, 2023, Agenus distributed a dividend of approximately 5,000,000 shares it owned of its subsidiary MiNK Therapeutics’ common stock to shareholders who held …
WebApr 30, 2023 · Agenus distributed a dividend of approximately 5,006,397 shares it owned in MiNK Therapeutics' common stock to shareholders who held Agenus shares as of April …
WebMar 30, 2023 · LEXINGTON, Mass.-- ( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer …
Skip to content
